HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM: NTEC) today announced the discontinuation of further development of NE-180 (GlycoPEGylated erythropoietin) based on an evaluation of commercial prospects and the likelihood of entering into a timely collaboration for the compound in the context of increased safety concerns in the erythropoiesis-stimulating agent (ESA) category. NE-180 is the Company’s product candidate for the treatment of anemia in patients with chronic kidney disease and cancer patients receiving chemotherapy. The decision to discontinue development is not due to any safety or efficacy concerns about NE-180. Read articles below.
